

MTN 039 - Safety and PK Study of TAF/EVG Administered Rectally
Report - December 6, 2022
Visit Cutoff Date: July 21, 2021¹
Retention by Visit and Site

	Pittsburgh	Birmingham	All Sites
Participants Enrolled	11	12	23
Visit 3: Dose 1			
Expected ²	11	12	23
Completed ³	10 (91%)	11 (92%)	21 (91%)
Not Completed	1 (9%)	1 (8%)	2 (9%)
Missed	0 (0%)	1 (8%)	1 (4%)
Terminated Early	1 (9%)	0 (0%)	1 (4%)
Not Expected	0	0	0
Visit 4: 24hr Post-dose			
Expected ²	11	12	23
Completed ³	10 (91%)	10 (83%)	20 (87%)
Not Completed	1 (9%)	2 (17%)	3 (13%)
Missed	0 (0%)	2 (17%)	2 (9%)
Terminated Early	1 (9%)	0 (0%)	1 (4%)
Not Expected	0	0	0
Visit 5: 48hr Post-dose			
Expected ²	11	12	23
Completed ³	10 (91%)	11 (92%)	21 (91%)
Not Completed	1 (9%)	1 (8%)	2 (9%)
Missed	0 (0%)	1 (8%)	1 (4%)
Terminated Early	1 (9%)	0 (0%)	1 (4%)
Not Expected	0	0	0
Visit 6: 72hr Post-dose			
Expected ²	11	12	23
Completed ³	10 (91%)	11 (92%)	21 (91%)
Not Completed	1 (9%)	1 (8%)	2 (9%)
Missed	0 (0%)	1 (8%)	1 (4%)
Terminated Early	1 (9%)	0 (0%)	1 (4%)
Not Expected	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 039 - Safety and PK Study of TAF/EVG Administered Rectally
Report - December 6, 2022
Visit Cutoff Date: July 21, 2021¹
Retention by Visit and Site

	Pittsburgh	Birmingham	All Sites
Visit 7: Dose 2			
Expected ²	11	12	23
Completed ³	9 (82%)	10 (83%)	19 (83%)
Not Completed	2 (18%)	2 (17%)	4 (17%)
Missed	0 (0%)	2 (17%)	2 (9%)
Terminated Early	2 (18%)	0 (0%)	2 (9%)
Not Expected	0	0	0
Visit 8: 24hr Post-dose			
Expected ²	11	12	23
Completed ³	9 (82%)	10 (83%)	19 (83%)
Not Completed	2 (18%)	2 (17%)	4 (17%)
Missed	0 (0%)	2 (17%)	2 (9%)
Terminated Early	2 (18%)	0 (0%)	2 (9%)
Not Expected	0	0	0
Visit 9: 48hr Post-dose			
Expected ²	11	12	23
Completed ³	9 (82%)	9 (75%)	18 (78%)
Not Completed	2 (18%)	3 (25%)	5 (22%)
Missed	0 (0%)	3 (25%)	3 (13%)
Terminated Early	2 (18%)	0 (0%)	2 (9%)
Not Expected	0	0	0
Visit 10: 72hr Post-dose			
Expected ²	11	12	23
Completed ³	9 (82%)	9 (75%)	18 (78%)
Not Completed	2 (18%)	3 (25%)	5 (22%)
Missed	0 (0%)	3 (25%)	3 (13%)
Terminated Early	2 (18%)	0 (0%)	2 (9%)
Not Expected	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 039 - Safety and PK Study of TAF/EVG Administered Rectally
Report - December 6, 2022
Visit Cutoff Date: July 21, 2021¹
Retention by Visit and Site

	Pittsburgh	Birmingham	All Sites
Final Contact			
Expected ²	11	12	23
Completed ³	9 (82%)	10 (83%)	19 (83%)
Not Completed	2 (18%)	2 (17%)	4 (17%)
Missed	0 (0%)	2 (17%)	2 (9%)
Terminated Early	2 (18%)	0 (0%)	2 (9%)
Not Expected	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.